Reports on the global diabetes industry news indicate that drug company Amylin Pharmaceuticals has suffered from poorer-than-expected sales of diabetic drug Byetta.
The pharmaceutical company reported a loss of $68.8 million, worse than that predicted by analysts, despite revenue climbing to $197.2 million. The company were understood to be disappointed with their results.
One of their major competitors, Merck, unveiled the relative success of type 2 diabetes drug Januvia. In response to the news, Amylin lowered revenue guidance for 2008.
The global diabetes industry is a competitive market, with numerous companies selling a variety of different drugs for diabetics . These companies include giants such as Glaxo SMith Kline and Novo Nordisk, not to mention much smaller biotechnology companies.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…